Clinical trials
Psilocybin clinical trials
Below are recruiting psilocybin clinical trials, each written for real people, not researchers. We’re tracking 103 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05866471RecruitingPhase 1
Testing nerve stimulation plus psilocybin for emotional well-being
This early safety study tests whether stimulating a nerve (taVNS) combined with psilocybin can change emotional well-being. It also checks safety issues like heart rhythms, lab results, and whether fMRI brain scans are possible.
Madison, WisconsinAges 18–70 - NCT05265546RecruitingPhase 1
Psilocybin study of changes in how you see
This Phase 1 study tests whether psilocybin affects visual perception and how visual information is represented in the brain. It also studies safety and what brain/vision changes happen after the dose.
Berkeley, CaliforniaAges 21 years+ - NCT05585229RecruitingPhase 2
Psilocybin therapy to help you taper opioid pain medicine
This Phase 2 study tests a structured, therapist-led treatment using standardized natural psilocybin to help people reduce or stop long-term opioid use for chronic (non-cancer) pain. It’s mainly for those who have tried tapering before but couldn’t, and who are motivated to try again.
Kelowna, British ColumbiaAges 19–75 - NCT05570708Enrolling by invitation
Therapist training trial on how experience shapes therapy
This study looks at how therapists’ personal experience affects their attitude and skills during substance-assisted therapy training. It’s mainly for therapists-in-training, and may help improve how future training and therapy are delivered safely.
BaselAges 27 years+ - NCT07703722RecruitingPhase 3
Psilocybin and therapy for depression with trauma
This trial tests psilocybin (a compound from certain mushrooms) combined with a structured therapy to see if it helps people with depression linked to trauma. It focuses on how the treatment affects the connection between the gut and brain.
Islamabad, CapitalAges 18–60 - NCT05398484RecruitingPhase 2/Phase 3
Psilocybin therapy for advanced cancer-related anxiety
This trial studies whether psilocybin (with support and therapy) can reduce anxiety in people with advanced cancer. It may help with distress and quality of life, while the study team monitors safety closely.
Aurora, ColoradoAges 21–100 - NCT05403086RecruitingPhase 2
Psilocybin for distress in people with serious, life-limiting illness
This Phase 2 study tests whether psilocybin therapy can reduce deep distress (“demoralization”) in people receiving palliative (comfort-focused) care. It may help with mood and well-being, but you must meet safety and medication requirements to join.
Greenbrae, CaliforniaAges 18 years+ - NCT05301608RecruitingPhase 1/Phase 2
Psilocybin study of brain activity and changing thoughts
This Phase 1/2 study tests psilocybin to see how it affects brain signals and the “content” of thoughts while you are monitored during the study. Because participants must be generally healthy and mentally stable, it may be an option if you meet those safety and medication rules and are comfortable having your brain activity measured.
Baltimore, MarylandAges 18–75 - NCT05068791RecruitingEarly Phase 1
Psilocybin-assisted treatment for long-term body pain
This early trial studies whether psilocybin, given in a supported setting, can reduce long-term widespread musculoskeletal pain (including fibromyalgia-like symptoms). You would be monitored closely and need someone to take you home after the medicine session.
Birmingham, AlabamaAges 25–65 - NCT04882839RecruitingPhase 2
Therapy with psilocybin for severe OCD symptoms
This Phase 2 study tests whether psilocybin-assisted psychotherapy can reduce symptoms in adults with severe, treatment-resistant OCD. It also focuses on safety and whether this approach is practical to run.
BeershebaAges 18–65 - NCT07732166RecruitingEarly Phase 1
Psilocybin and Self-Awareness Study
This trial tests whether a single dose of psilocybin (a psychedelic substance) can change self-awareness in healthy adults. It aims to understand how this substance affects the brain, which might lead to new mental health treatments.
Rio de Janeiro, Rio de JaneiroAges 21–60 - NCT04123314RecruitingEarly Phase 1
Psilocybin study for depression in mild memory or early Alzheimer’s
This early-phase study tests whether psilocybin (a psychedelic substance) can help with depression in people who have mild memory problems or early Alzheimer’s. The trial also closely monitors safety, thinking changes, mood, and blood pressure before and after dosing.
Baltimore, MarylandAges 18–85 - NCT07737054RecruitingEarly Phase 1
Psilocybin therapy for PTSD
This trial tests a type of therapy that uses psilocybin (a safe, natural substance found in certain mushrooms) to help people with PTSD. It combines talk therapy with the medicine to see if it can reduce trauma symptoms.
Tel AvivAges 21–65 - NCT07818564RecruitingPhase 1
Psilocybin study on belief and insight in healthy adults
This study tests whether a single dose of psilocybin (a psychedelic compound) can help people update their beliefs and gain new insights. It's for healthy adults with some prior psychedelic experience, and it's a small pilot study at Brown University.
Providence, Rhode IslandAges 18 years+ - NCT07721467RecruitingPhase 2
Cognitive training with psilocybin for brain flexibility
This study tests whether combining a brain-training program with a psychedelic drug called psilocybin can boost the brain's ability to change and adapt. It may help improve thinking and memory.
Baltimore, MarylandAges 65–120 - NCT07565493RecruitingEarly Phase 1
Psilocybin with a serotonin blocker in healthy adults
This early-stage research study tests how psilocybin (a naturally occurring compound from certain mushrooms) works when combined with a medication that blocks a specific serotonin pathway in the brain. Researchers want to understand how these two substances interact in healthy volunteers to inform future psychiatric treatment studies.
Baltimore, MarylandAges 21–60 - NCT07607938RecruitingPhase 1
Psilocybin for Depression With Loss of Interest or Pleasure
This study tests whether psilocybin, a naturally occurring psychedelic compound, can help people with depression who experience anhedonia—a loss of interest or pleasure in activities. Researchers will monitor your brain activity and mood changes over time to see if this treatment is safe and helpful.
New York, New YorkAges 18–65 - NCT07516405RecruitingPhase 1
Psilocybin Safety Study in Older Adults
This research tests whether psilocybin (a psychoactive compound from certain mushrooms) is safe and well-tolerated in healthy people aged 65–85. Researchers want to understand how older adults respond to this substance and whether it could be useful for future treatments.
San Francisco, CaliforniaAges 65–85 - NCT07610369RecruitingPhase 2
Psilocybin therapy for depression in Parkinson's disease
This study tests whether psilocybin (a psychedelic compound) combined with therapy can reduce depression in people with Parkinson's disease. If you have moderate-to-severe depression and Parkinson's, this trial may offer a new treatment option.
New Haven, ConnecticutAges 40–80 - NCT07610135RecruitingPhase 1/Phase 2
Psilocybin with or without pimavanserin pretreatment
This trial tests whether taking pimavanserin before psilocybin changes the drug's effects in healthy volunteers who have never used psychedelics. It aims to understand how to make psychedelic therapy safer and more predictable.
Baltimore, MarylandAges 21–65 - NCT07490353RecruitingPhase 1
Can psilocybin help treat loss of pleasure?
This trial tests if psilocybin, a psychedelic substance, can improve the ability to feel pleasure (anhedonia) in people with depression who are not taking antidepressants. It also includes healthy volunteers as a comparison group.
Vienna, State of ViennaAges 18–55 - NCT07386730RecruitingPhase 1
Psychedelic therapy study for older adults with low well-being
This study tests if a single dose of psilocybin (a psychedelic) or dextromethorphan (a cough suppressant) can improve well-being in healthy older adults who feel their well-being is below average. It aims to understand how these drugs might help boost mood and life satisfaction.
San Francisco, CaliforniaAges 50–85 - NCT07053917RecruitingPhase 1
Psilocybin therapy for stroke recovery
This trial tests whether a medicine called psilocybin (a psychedelic compound) can help people who had a stroke more than a year ago. It aims to see if the therapy can improve healing and flexibility in the brain.
Baltimore, MarylandAges 18 years+ - NCT06898606RecruitingPhase 1/Phase 2
Psilocybin mushrooms with or without Prozac for stubborn depression
This study tests whether a dose of psilocybin (the active ingredient in magic mushrooms) can help treat depression that hasn't improved with standard antidepressants. Some participants will also take the antidepressant fluoxetine (Prozac) to see if it changes the effects.
Foz do Iguaçu, ParanáAges 25–65
Hear when a new Psilocybin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psilocybin?
- Yes. Clin2 currently lists 103 recruiting psilocybin studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psilocybin trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psilocybin trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.